Screener
Corvus Pharmaceuticals CRVS PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts receivable - related party | 43 | 37 |
| Prepaid and other current assets | 3,189 | 1,427 |
| Total current assets | 239,946 | 58,214 |
| Property and equipment, net | 282 | 220 |
| Operating lease right-of-use asset | 751 | 839 |
| Investment in Angel Pharmaceuticals | 10,496 | 10,991 |
| Other assets | 1,720 | 855 |
| Total assets | $253,195 | $71,119 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's PP&E (net)?
- Corvus Pharmaceuticals (CRVS) reported PP&E (net) of $282K in Q1 2026.
- How has Corvus Pharmaceuticals's PP&E (net) changed year-over-year?
- Corvus Pharmaceuticals's PP&E (net) increased by 70.9% year-over-year, from $165K to $282K.
- What is the long-term trend for Corvus Pharmaceuticals's PP&E (net)?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's PP&E (net) has grown at a -24.7% compound annual growth rate (CAGR), from $906K to $220K.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Corvus Pharmaceuticals's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude